Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.56 |
| ▸ | HTR2A | P28223 | 4/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26782443 | 0.90 | HTR2A (0.50) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL26053886 | 0.89 | TAAR1 (0.46) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL10019206 | 0.88 | MAPT (0.49) | TAAR1HTR2A | |
| SCHEMBL18867916 | 0.86 | HTR2A (0.50) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL14113379 | 0.85 | HTR2A (0.70) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| Dom SCHEMBL1742173 | 0.85 | HTR2A (0.76) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| Dom SCHEMBL398119 | 0.85 | HTR2A (0.76) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| Dom SCHEMBL988769 | 0.83 | HTR2A (0.73) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL18757899 | 0.83 | HTR2A (0.51) | TAAR1HTR2A | |
| SCHEMBL5306335 | 0.82 | TAAR1 (0.50) | TAAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265045-A1 | PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-8101661-B2 | Polar hydrophilic prodrugs and non-standard amino acid conjugates of amphetamine and other stimulants and processes for making and using the same | KEMPHARM, INC. (US) | 2012-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265045-A1 | PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS | PNMT, HTR2C, HTR2A | TAAR1 66/4885HTR2A 3/4885HTR1A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.